FDAnews
www.fdanews.com/articles/100573-human-genome-sciences-completes-enrollment-in-albuferon-trial

Human Genome Sciences Completes Enrollment in Albuferon Trial

November 2, 2007

Human Genome Sciences has started dosing in ACHIEVE 2/3, the second of two Phase III trials of Albuferon in combination with ribavirin in treatment-naive patients with chronic hepatitis C.

The two randomized, open-label, active-controlled, multicenter, noninferiority trials, ACHIEVE 1 and ACHIEVE 2/3, will evaluate the efficacy, safety and quality of life of Albuferon (albinterferon alfa-2b) in combination with ribavirin versus Pegasys (peginterferon alfa-2a) in combination with ribavirin.

ACHIEVE 2/3 enrolled 933 patients with genotypes 2 and 3 chronic hepatitis C. ACHIEVE 1 completed enrollment of 1,331 treatment-naive patients with genotype 1 chronic hepatitis C in August, Human Genome Sciences said.

Higher doses of monthly Albuferon in combination with ribavirin will be explored in a separate Phase IIb trial conducted by Human Genome Sciences’ partner Novartis.